US Stock MarketDetailed Quotes

ACRV Acrivon Therapeutics

Watchlist
  • 8.460
  • -0.010-0.12%
Close Apr 26 16:00 ET
  • 8.590
  • +0.130+1.54%
Post 16:24 ET
261.18MMarket Cap-3087P/E (TTM)

About Acrivon Therapeutics Company

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Company Profile

SymbolACRV
Company NameAcrivon Therapeutics
Listing DateNov 15, 2022
Issue Price12.50
Founded2018
CEOMr. Peter Blume-Jensen, M.D.,PhD
MarketNASDAQ
Employees61
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address480 Arsenal Way,Suite 100
CityWatertown
ProvinceMassachusetts
CountryUnited States of America
Zip Code02472
Phone1-617-207-8979
Websitehttp://acrivon.com

Company Executives

  • Name
  • Position
  • Salary
  • Peter Blume-Jensen, M.D.,PhD
  • Chairman of the Board, President and Chief Executive Officer
  • 21.69M
  • Dr. Erick Gamelin, M.D.,PhD
  • Chief Medical Officer
  • --
  • Dr. Eric Devroe, PhD
  • Chief Operating Officer
  • --
  • Rasmus Holm-Jorgensen
  • Chief Financial Officer and Principal Accounting Officer
  • 1.72M
  • Dr. Kristina Masson, M.B.A.,PhD
  • Executive Vice President, Business Operations and Director
  • --
  • Dr. Ivana Magovcevic-Liebisch, J.D.,PhD
  • Director
  • --
  • Santhosh Palani, C.F.A.,PhD
  • Director
  • --
  • Dr. Charles M. Baum, M.D.,PhD
  • Independent Director
  • --
  • Dr. Sharon Shacham, M.B.A.,PhD
  • Independent Director
  • 322.50K
  • Dr. Derek DiRocco, PhD
  • Independent Director
  • 323.13K
  • Michael J. Tocek, M.B.A.
  • Independent Director
  • 323.75K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg